Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance

AbbVie IncTrade
iShares 3 7 Year Treasury Bond ETFTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs iShares 3 7 Year Treasury Bond ETF — how do they compare? AbbVie Inc trades at $247.41 (market cap $441.94B), while iShares 3 7 Year Treasury Bond ETF trades at $116.54. The key difference: AbbVie Inc pays a 2.77% dividend while iShares 3 7 Year Treasury Bond ETF pays none, and AbbVie Inc is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.

ABBVIEI
Market Cap
$441.94B
Sector
HealthFixed Income
52-Week High
$263.58$120.72
52-Week Low
$197.38$116.16
Enterprise Value
$506.19B
Dividend Yield
2.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.

Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.

iShares 3 7 Year Treasury Bond ETF

IEI, the iShares 3-7 Year Treasury Bond ETF, trades at $116.565, up 0.27% today, with technical indicators showing a bearish trend from moving averages and neutral oscillators. Recent news highlights institutional activity, including Bank of America increasing its stake by 39.7% in the latest quarter (Defense World, 2026-08-01). The fund maintains a conservative profile with regular dividend distributions, appealing to income-focused investors amid volatile bond markets.

The outlook for IEI is cautious due to rising Treasury yields and inflation concerns, posing risks from potential Fed rate hikes. However, its government backing and lower volatility offer stability for risk-averse portfolios, with income generation from dividends remaining a key attraction despite macroeconomic headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About iShares 3 7 Year Treasury Bond ETF

IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.

Read more on IEI